Nov 12, 2012 ... R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular
Pharmacology. The Wählby lecture format. ▫ Geometric properties.
2012-11-12
The Wählby lecture format
Geometric properties
Microscopy
Geometric properties Spectral properties Temporal properties Access Quantitative aspects
Focus: Industrial/applied science
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Epi-fluorescent, bright field, (confocal, multi-photon, electron)
Densitometric properties R
G
B
Non-optical methods plasmons, gratings, electrodes, mass-spec
Sample properties
(auto) fluorescence, refractive index, thickness, polarizing Uneven distribution, cell cultures, tissues (volumes, stereology) Artifacts: folds, tears, scratches, dust Variable thickness movement
Live cell imaging, 3D imaging, 4D imaging
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Epi-fluorescent systems • Automated, robotic • Slides – 1536 well • 2 – 60x • Up to about 0.9 NA • Mostly air objectives • + robotic arms
Geometric properties Densitometric properties Spectral properties Temporal properties
Brightfield systems • Live cell analysis • Slide scanning systems
Access Quantitative aspects
Focus: Industrial/applied science
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
1
2012-11-12
Plasmons Gratings (Bind Scanner)
Sample stability: Fixatives
Cellular dielectric Spectroscopy (CellKey)
Multi electrode arrays
formaldehydes, glutaraldehydes, alcohols, parafin
Fixation will affect your sample Stability N2 atmosphere Antigen presentation – different for different fixatives
Antigen retrieval – the magic solution Temperature, pH, enzymatic digestion Mass spec imaging
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Sample stability: RNA imaging
DNA
GAPDH mRNA
GAPDH protein
Optical thickness of sample holder Phase contrast in narrow wells Polarisation Refractive index (plastics, wells with fluids) Oil and water objectives problematic
Tears, folds, scratches, dust Uneven sample distribution overlay
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
In tissue (Stereology) During preparation On slide
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
2
2012-11-12
Sample distribution: density affects expression Low density Hoechst
High density Drebrin
Hoechst
Drebrin
Normalised cell density
Cell density vs. Cell number Log(cell density) vs cell number
Sample distribution
Spherical objects Neurospheres Pancreatic islets
Cell number (nucleii) Cell density ≠ cell number. Density increases exponentially with linear increases in cell number. R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Sample distribution: small moving objects
PCS
Ampho
granules [Aβ] -6
Z
Time
Y X
-11
Image at multiple time points in each well
3 Z positions/site 4 sites/well = 12 images/ time point/well
density
>46000 images for one 384-well plate
Time
[Aβ]
A
[Aβ]
Antibiotic choice does affect cellular density. Density affects amyloid binding. Does density affect the drebrin response to amyloid? R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Z
Deconvoluted images created from each z-stack Using nearest neighbours method or ”remove haze”
B
C
D
E
F
B-A
C-B
D-C
E-D
F-E
”Difference” images created (temporal colocalisation) Fading, Dial in sensitivity by selecting interval, Normalisation
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
3
2012-11-12
Densitometric properties Good samples, good images Variable? -> Many images/samples
Fluorescence vs. reflected light (brightfield) Signal enhancement, pre-detector Washing, TSA, Duo-Link, dye efficiency Autofluorescence (sample/mounting material)
Signal enhancement @ detector Detectors (bit depth, pixel size/binning, cooling)
Signal enhancement post detector Multishot techniques, Increase resolution, reduce noise
Image compression
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Geometric properties Densitometric properties Spectral properties
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
”Sample preparation. Sample preparation. Sample preparation.”
Temporal properties Access Quantitative aspects
Focus: Industrial/applied science
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
4
2012-11-12
Dealing with 2D spatial variation Low density Hoechst
Signal enhancement Pre-detector
High density Drebrin
Hoechst
Drebrin
Sample prep sample prep sample prep Wash thoroughly – robotics Reduce non-specific binding Reduce autofluorescence Thin substrate important Long wavelenths
Don’t wash at all Extra cellular quenchers Dyes and Pre-dyes
Chemical enhancers
Acquire many images Dynamic imaging
TSA, PLA (next slide) Permeabilisation
Images are aquired until appropriate number of pre-defined events occurs
Methanol, acetone – dissolve membranes (lipids) Saponin – removes cholesterol Triton X-100, tween-20 – can extract proteins
Pre-scan at low mag, rescan regions of interest (ROI) at high mag R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
1 bit (2)
Single molecules: (Trk A, NGF) and PLA 2 bit (4)
4 bit (16) Typical dynamic ranges for: Fluorescence
10, 12, 16 bit (4096, 16384, 65536 levels) Brightfield
8 bit (256)
8, 10, 12 bit/channel Phase contrast
8, 10 bit R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
5
2012-11-12
Signal enhancement At the detector
Bit depth Binning/bigger sensor Gain Cooling Decreased noise
Signal enhancement Post detector
Geometric properties Densitometric properties Spectral properties Temporal properties Access Quantitative aspects
Multishot techniques:
Average – removes noise Median – removes moving objects
Focus:
Sum/integration – enhance signals
Industrial/applied science
Resolution enhancement Deconvolution
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Spectral properties Microscopy Epi-fluorescent, confocal, multi-photon, bright field, electron
Illumination Emission spectra: mercury, xenon, diodes, lasers Vigneting/uneven illumination, illumination changes over time
Systems can be spectrally calibrated/characterised Intensity, alignment, PSF
Sample standards do not exist (yet) Variable parameters Humidity, temperature, pressure, osmolarity, viscosity, refractive index, fluid meniscus, possibly sample container dimensions + thickness
Filter bleed R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
6
2012-11-12
Diodes Very stable over time Long lifespan Faster wavelength switching
Much less heat
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Illumination artifacts
Calibration
Can be detected statistically during automated QC Obvious when you have many images Original
Arc burn on reflector
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Technical standards PSF, spherical aberation
No biological standards
Vignetting
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
7
2012-11-12
Optimisation of live-cell experiments
Quantifying filter bleed
Different operating temperatures
Can be performed in every plate for each Various speeds and run times Four types of tips Injection height, speed, position
Different magnifications
Four types of plate
Five different Ca-sensitivedyes
experiment (384, possibly 96)
Image all wells with 4 colours Control wells contain only 1 colour Signals in irrelevant channels quantified Subtract appropriate fraction of each channel from other channels
Similar to ”compensation” in flow
Blue Green Yellow
cytometry
Time consuming Not usually necessary
Red
Different buffer systems
Three types of foil
Reproducibility Stability R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Physical factors and spectral characteristics Temperature Cold plate in warm machine = condensation
Evaporation Changes osmolarity, density, miniscus level Not uniform: edge effects
Biological coatings Poly-D-lysine, collagen, laminen, finger prints Variable optical thickness – focusing challenge
Geometric properties Densitometric properties Spectral properties Temporal properties Access Quantitative aspects
Focus: Industrial/applied science
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
8
2012-11-12
Normalisation to positive control at pixel level = good assay
Temporal properties
14000000
IX-background
Mean intensity
12000000
Experimental design is important Live cell 3 and 4D imaging – images + time! Sampling frequency
FLIPRator
10000000
IX-cell specific
8000000 6000000 4000000 2000000 0 0
50
Hardware mods: filter wheels, spinning disks, line scanners Higher frequency, lower signal
2000000
Z´= - 0.96
1500000
Mean raw intensities
1000000
Sample stability
500000 0
Viability, osmolarity, atmosphere, dye distribution/stability Reagent stability, mixing
min
120 100 80 60 40 20 0
16 sec.
Mean normalised intensities
max
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Automated Image Analysis of live cell responses 64 sec.
max
Z´= 0.8
min R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
16 sec.
100
Time (sec)
Functional population segmentation using agonists
16 sec.
KCl-sensitive cells represent about 3.2% of the total population (4.7% beta-III tubulin). Baseline acquisition
First injection (e.g. trypsin)
Second injection (+ve control)
Third injection (+ve control)
About 10% of these respond to capsaicin (0.3% of total population).
(Frame alignment) Baseline images averaged Subtract average baseline (pixel level background subtraction)
Capsaicin
KCl
A23187
overlay
100
Positive control(s) used to identify image ROIs
80
Measure only in ROIs at each timepoint
60
Disregard cells that move or disappear
40
Cellular or image level
Normalised data and statistics generated for each timepoint (Z´= 0.8)
Baseline
120
20
Segmentation
0 0
20
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
40
60
80
100
120
Four populations
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
9
2012-11-12
Identify subpopulations with morphology
Responses to 25 nM trypsin in three cellular populations
Measure responses
60
fuzzy cells
50
buffer
small cells
Fuzzy/Glial/ Schwann trypsin
neurons
40 Average intensity 30 Fold change from baseline 20
Small/Fibro- buffer blasts
trypsin
10
buffer
neurons
trypsin
0 0
20
40 60 Time (sec)
80
100
0
60
fuzzy cells
small cells neurons
40 Average intensity 30 Fold change from baseline 20
50
1000
fuzzy cells
50
10 20 30 40 average fold change from baseline
small cells
neurons
100 Average Number of cells analysed
10
10 1
0 110
11
1.1
0.11
110
trypsin buffer
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
1.1
0.11
trypsin buffer
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Temporally separated agonist responses in
Temporal properties
functional populations identified using morphology Original
11
Trypsin inhibitor ug/ml
Trypsin inhibitor ug/ml
Baseline subtracted
120 100 80 60
Experimental design is important Live cell 3 and 4D imaging Sampling frequency
40 20 0 0
20
40
60
80
100
120
Hardware mods: filter wheels, spinning disks, line scanners Higher frequency, lower signal Incremental change
Morphometric populations: glial/Schwann fibroblasts
Sample stability = lots of quality control Viability, osmolarity, atmosphere, dye distribution/stability Reagent stability, mixing
neurons
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
10
2012-11-12
1
2
3
4
5
6
7
8
9
10
11
12
A B C D
buffer 50 nM tryp
E F G H
50 nM tryp buffer
buffer 50 nM tryp
50 nM tryp buffer
buffer 50 nM tryp
50 nM tryp
buffer 50 nM tryp
buffer
50 nM tryp
buffer 50 nM tryp
buffer
50 nM tryp
buffer 50 nM tryp
buffer
Geometric properties Densitometric properties Spectral properties Temporal properties Access Quantitative aspects
50 nM tryp buffer
Focus: Industrial/applied science
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Responses are fairly stable over an entire plate 150 125
Time (min) buffer
100
*
75
125
10
15
Time (sec)
trypsin - buffer
0 24 48
75
72
50
96
25
120
0 -50
144 168
100
-25 0
75
120 5
-50 150
100
48 96
25 0 -25 0
125
24 72
50
5
10
15
144 168
Time (sec)
150
0
Access
Time (min) 0
trypsin
24 48 72
50
96
25
**
120
0 0
-25 -50
5
10
144
15
168
Time (sec)
sum
200 100 0 -100 -200 -300
Time (min)
consumables, training and education, per well cost (multiplexing)
Fairly common Standard high-throughput methods in industrial and major academic settings
400 300
Cost – large initial investment,
**
Set-up time, appropriate method Limited expertise
*
Time (min)
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
11
2012-11-12
Software
Geometric properties Densitometric properties Spectral properties
A lot of (expensive) proprietry software Often unique to each platform
General image analysis packages: MetaXpress (high throughput MetaMorph variant) SQL-based, high level but powerful scripting language Extensive hardware control Fairly open, reads anything Cellomics BioApplications Predefined (but very fast) analysis algorithms Very closed Visiopharm, BioPix, Definiens for morphology Definiens, MatLab Very competent, extreme learning curves Spotfire, R (open source), DeNovo FCS image Multidimensional data analysis
Temporal properties Access Quantitative aspects
Focus: Industrial/applied science
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Quantitative aspects
Computing resources in the industrial setting (hard/software) Image processing: common methods, but automated Multidimensional data analysis: Spotfire, R and FCS Image Data presentation/storage The best way to present complex data Buy yourself a nice TV: good for data, good for movie nights
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Open source/freeware:
Fiji/imageJ Cell profiler/analyst Phenoripper Volocity
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Data management and hardware SQL/Oracle/proprietry databases NAS or SAN drives, (n) Tb Backup?
High speed, low latency network Clusters of cores for analytical work (blade servers) Parallel processing Pipelin Pilot Lakshmanan
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
12
2012-11-12
Functional population segmentation using agonists
Image processing
KCl-sensitive cells represent about 3.2% of the total population (4.7% beta-III tubulin).
Common to microscopy: QC (focus, artfacts) Illumination correction (generally not used, low dignals only) Deconvolution, thresholding, feature extraction Local background detection Textures, phenotypes Controls: Technical, biological
About 10% of these respond to capsaicin (0.3% of total population).
Typical examples: Expression (protein, RNA), phenotyping Binding Translocation, internalisation, transport (vessicles, organelles) Apoptosis, proliferation, micronucleation Membrane shape, cell movement Morphology (phenotypic screening) Functional responses (shape, signaling, secretion...)
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Translocation
Baseline
Capsaicin
KCl
A23187
overlay
Segmentation Four populations
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Binding
So, now you have your data...
Toxicity
Neurite outgrowth
Proteolysis
No‐Doxycycline
4 sites/well 4 colors/site 300 cells/image 20 measurements/cell 15 plates
15
384 wells/plate
5760 23040 92160 27648000 552960000 data points
Doxycycline 5µg/ml
Induced expression R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
13
2012-11-12
Thanks for your attention!
Quantitative aspects
Software in the industrial setting Image processing... Multidimensional data analysis: Spotfire, R and FCS Image Data presentation/storage The best way to present complex data (simple?) Buy yourself a nice TV: good for data, good for movie nights The High Content Imaging Unit AstraZeneca, CVGI Cell and Molecular Phamacology Mölndal, Sweden
[email protected]
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Geometric properties Densitometric properties Spectral properties Temporal properties Access Quantitative aspects
Focus: Industrial/applied science
R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 2 Kingdom Street, W2 6BD, London, UK, Tel: +44(0)20 7604 8000, Fax: +44 (0)20 7604 8151, www.astrazeneca.com R&D | Innovative Medicines | CVGI Mölndal | Dept. of Cell and Molecular Pharmacology
14